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Original article
Influenza vaccination in pregnancy among a 
group of remote dwelling Aboriginal and Torres 
Strait Islander mothers in the Northern Territory: 
The 1+1 Healthy Start to Life study
Lisa McHugh, Michael J Binks, Yu Gao, Ross M Andrews, Robert S Ware, Tom Snelling 
and Sue Kildea.
Summary
We found uptake of inactivated influenza vaccine (IIV) in pregnancy in remote-living Aboriginal 
and Torres Strait Islander women from the NT of Australia was 0% for the pre-influenza A(H1N1)
pandemic period (A(H1N1)pdm09) from 2003 to 2006, and remained unacceptably low (7%) for the 
post-influenza A(H1N1)pdm09 period (>2009–2011). Although IIV was routinely recommended for 
pregnant women throughout the entire eight year study period, vaccine uptake was extremely low 
among the 697 pregnancies in our study, particularly in women with known comorbidities and/or 
high risk factors.
Abstract
Remote-living Aboriginal and Torres Strait Islander women experience a higher burden of influenza 
infection during pregnancy than any other Australian women. Despite recommendations of inacti-
vated influenza vaccination (IIV) in pregnancy, uptake and safety data are scarce for this population. 
We examined uptake of IIV in pregnancy and report adverse birth outcomes amongst a predominantly 
unvaccinated group of remote-living Aboriginal and Torres Strait Islander women from the Northern 
Territory (NT), using data from the 1+1 Healthy Start to Life study. Data were deterministically linked 
with the NT Immunisation Register to ascertain IIV exposure in pregnant women during 2003–2006 
and 2009–2011 inclusive. Overall, IIV uptake in pregnancy was 3% (n=20/697 pregnancies); 0% (0/414) 
pre-influenza A(H1N1)pdm09 and 7% (20/293) post-influenza A(H1N1)pdm09 (2009–2011). Vaccine 
uptake was poor in this cohort and it is unclear at what stage this policy failure occurred. Women with 
known comorbidities and/or high risk factors were not targeted for vaccination. Much larger study 
participant numbers are required to validate between group comparisons but there was no clinically 
nor statistically significant difference in median gestational ages (38 weeks for both groups), mean 
infant birthweights (3,001 g unvaccinated vs 3,175 g IIV vaccinated), nor birth outcomes between the 
few women who received IIV in pregnancy and those who did not. There were no stillbirths in women 
who received an IIV in pregnancy.
Keywords: Influenza, remote, Northern Territory, pregnancy, birth outcomes, vaccination, uptake, 
Aboriginal, Australia
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Introduction
Pregnant women are a high priority for seasonal 
inactivated influenza vaccination (IIV) world-
wide.1 Pregnant women and infants bore a dis-
proportionately high burden of illness during the 
2009 influenza A (H1N1) pandemic (influenza 
A(H1N1)pdm09),2,3 where 30–50% of women 
of child-bearing age who died were pregnant.4,5 
The disease burden from influenza infection was 
particularly high amongst pregnant Indigenous 
women in Canada, the Americas and the Pacific, 
including Australia,6–8 where the risk of severe 
disease and death from influenza A(H1N1)
pdm09 was 3–12 times higher than for non-
Indigenous populations.7,9
Aboriginal and/or Torres Strait Islander (hereaf-
ter respectfully referred to as Aboriginal) women 
and their infants continue to experience a higher 
burden of influenza infection during pregnancy 
and early infancy compared to non-Aboriginal 
Australians,10 and are disproportionately over-
represented during influenza pandemics with 
higher rates of hospitalisations and intensive 
care unit (ICU) admissions.11 Australian infants 
younger than six months of age incur up to 320 
annual hospitalisations per 100,000 population, 
of which one in 10 are admitted to an ICU.12,13 
Laboratory-confirmed influenza notifications 
and average annual notification rates in Northern 
Territory (NT) women of child-bearing age 
(15–<50 years) from 2008 to 2012 also showed 
a marked disproportionate burden of illness in 
Aboriginal women compared to non-Aboriginal 
women of the same age group.13,14
In March 2000, a recommendation for seasonal 
IIV was added to the Australian National 
Immunisation Program (NIP) for all women 
who would be pregnant during the influenza 
season, regardless of trimester of pregnancy, 
and the program became funded (free) in 2010.15 
The safety of maternal vaccination and vaccine 
provider recommendation are known to be the 
key drivers influencing the uptake of IIV in 
pregnancy.16,17 Given there is a disproportion-
ate disease burden from influenza infection 
amongst Aboriginal Australians,18 the available 
data on seasonal IIV uptake and safety for preg-
nant Aboriginal women is scarce, particularly 
for those women living in remote areas where 
the disease burden may be even greater. A World 
Health Organization (WHO) report published 
in 2017, examining the epidemiology of influ-
enza in pregnancy, found robust safety data in 
the form of randomised controlled trials (RCTs) 
were still lacking, with birth outcomes reported 
from observational studies conflicting and at 
risk of bias.19 A separate review of the safety of 
immunisation during pregnancy by the WHO 
has also recommended that further safety evi-
dence is needed for high-risk groups and local 
Indigenous populations.20
The primary aim of this study was to ascertain 
seasonal IIV uptake in pregnancy amongst a 
cohort of remote-living Aboriginal women in 
the NT. Subject to adequate IIV uptake, the sec-
ondary aim was to compare key birth outcomes 
between IIV-vaccinated and unvaccinated 
pregnant women.
Methods
Study design
We conducted retrospective cohort analyses 
using data collected from the ‘1+1 Healthy Start 
to Life’ study (1+1HS).21 Briefly, the 1+1HS study 
was designed to examine the utilisation and 
quality of health services and subsequent mater-
nal and infant health outcomes of Aboriginal 
women residing in remote communities in the 
NT over two time periods: before (2003–2006) 
and after (2009–2011) a significant service rede-
sign. Throughout the study period, pregnant 
women were routinely transferred to Royal 
Darwin Hospital (RDH) to birth their baby. 
Those mothers who were ≥20 weeks gestation 
with a singleton infant that weighed ≥400 grams 
(g) at birth were included. Women who birthed 
more than one infant within the study period 
were identified, and women pregnant with twins 
were excluded from the data analysis on adverse 
birth outcomes. Maternal and infant community 
health centre and regional hospital records were 
manually audited for each study participant, 
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then linked with demographic, comorbidity 
and risk factor data, health utilisation and cost 
and maternal and infant health outcomes. This 
became the final 1+1HS dataset.
Identifiable 1+1HS data were then deterministi-
cally linked with the NT Immunisation Register 
(NTIR) using the maternal identification num-
ber (ID) as the common identifier to confirm 
and validate maternal vaccination status in preg-
nancy. The NTIR is a population-based dataset 
of all immunisations administered in the NT. 
Clinical record checks were conducted manu-
ally for records where discrepancies occurred 
between the 1+1HS and NTIR datasets. Data 
cleaning was conducted to identify duplicates, 
multiple births and repeat birth, non-twin sib-
lings. Missing data were treated as such.
Maternal vaccine exposure
The primary exposure of interest was any 
influenza vaccination given during pregnancy, 
defined as a vaccine received between the first 
day (date) of the last normal menstrual period 
and the date of birth of the infant. Vaccination 
status in pregnancy was determined by using the 
date of vaccination, gestation in weeks at birth 
of the infant and the date of birth of the infant. 
Records of IIV obtained from the NTIR were 
dropped if the dates of IIV did not correlate with 
IIV during pregnancy or during the 12 months 
prior. Brand names and dosages of any vaccines 
received by each woman were ascertained, how-
ever batch-specific details were not available. The 
number of days from receipt of IIV in pregnancy 
until birth of the infant was recorded.
Birth outcomes
The primary birth outcomes of interest were: pre-
term births—infants born >20 weeks gestation, 
>400 g and <37 completed weeks’ gestation;22 
low birth weight (LBW)—any infant born >20 
weeks and <2,500 g;23 and small for gestational 
age (SGA)—infant birthweight <10th percentile 
calculated using Australian specific national 
birthweight percentiles by sex and gestational 
age.24 Maternal risk factors for adverse birth out-
comes were recorded for all study participants 
(Box 1).
Box 1: Maternal comorbidities and risk factors 
collected from 1+1HS study participants, 
2003–2011.
• Attended antenatal care in the 1st trimester 
(Y/N)
• Smoking in pregnancya (Y/N)
• Pregnancy complicationb
• Previous poor obstetric outcomec
• Rheumatic heart disease
• Cardiac condition
• Diabetesd
• Renal disease
• Asthma
• Maternal anaemia
a Recorded at first antenatal visit and at 36 weeks gestation
b Includes threatened preterm labour, preterm rupture of 
membranes, antepartum haemorrhage, placental abruption, 
placenta praevia, urinary tract infection (UTI), sexually 
transmitted infection (STI), gestational hypertension, pre-
eclampsia
c Includes previous history of preterm birth, stillbirth, neonatal 
death (in multiparous women)
d Includes type 1, type 2 and gestational diabetes
Data analysis
Data from the NTIR were merged with the 1+1HS 
dataset using the maternal identifier to calculate 
the proportion of women who received an IIV 
in pregnancy, by study year. Demographic, 
comorbidity and risk factor characteristics 
of mother-infant pairs were summarised and 
compared between women who received an IIV 
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during pregnancy and mothers who did not. 
Proportions were calculated; chi2 analyses for 
binary and categorical variables; and, depend-
ing on the distribution of the data, t-tests and 
ranksum analyses to calculate means and medi-
ans for continuous variables. We conducted Cox 
proportional-hazard ratio analyses for time-
dependent birth outcomes using the continuous 
variable ‘gestational age’ as the time-scale vari-
able. Compared to the unexposed group (unvac-
cinated pregnant women), in the exposed group 
(women who received IIV in pregnancy), the 
number of days from receipt of IIV in pregnancy 
until the birth of the infant was used to calculate 
effect estimates. Effect estimates are presented as 
crude hazard ratios (HR) with 95%CI. Data were 
analysed using Stata v.14.1 (StataCorp, College 
Station, Texas).
Results
There were 576 women with 697 pregnancies 
and 697 individual infants who were included 
in the cohort over the two observation periods: 
1 December 2003 – 31 December 2006 and 1 
January 2009 – 31 June 2011 (Figure 1). There 
were 121 mothers (17%) who birthed more than 
one infant (repeat births).
There were nine women who birthed twins (n=18 
infants), and none of these women received IIV 
in pregnancy. These women were henceforth 
excluded from further data analysis due to 
known confounding effects for preterm birth, 
LBW and SGA outcomes. Data linkage with the 
NTIR found a matching record for all 1+1HS 
study participants apart from three, who were 
excluded. A further six women who received 
dTpa (pertussis) vaccine in pregnancy were also 
excluded, none of whom had received an IIV in 
pregnancy.
Uptake
Of the 697 pregnancies, 20 women (3%) received 
IIV in pregnancy and 677 (97%) women were 
unvaccinated. The median time from receipt 
of IIV until birth of the baby was 9 weeks 
(range 1.9–22.6), or in days 63 (range 13–158). 
Ten women received IIV in the third trimester 
of pregnancy, all of whom were vaccinated 
approximately two weeks before the birth of the 
infant. Nine women received IIV in the second 
trimester and one in the first trimester. Seasonal 
IIV uptake in pregnancy during 2003–2006 
inclusive (pre influenza A(H1N1)pdm09) was 
zero (0/414). In 2009, six IIVs were given from 
July to November, commencing two months 
after the first case of influenza was detected 
in the NT. During 2009–2011 inclusive (post-
influenza A(H1N1)pdm09), uptake was 20/293 
(7%). There were no data collected in 2007 and 
2008 (Table 1).
Maternal characteristics, comorbidities 
and risk factors
The median maternal age of study participants 
at birth of their infant was 24 years for women 
who received IIV in pregnancy (range in years 
13–41) and unvaccinated pregnant women 
(range in years 18–41); 31% were primiparous 
women and 53% of infants born were male. 
There were 281 women (42%) who presented for 
antenatal care in the first trimester, with 11 (4%) 
of these receiving IIV in pregnancy. The median 
gestation in weeks at first presentation for ante-
natal care was 13 (range 7–28) for women who 
received IIV in pregnancy and 16 (range 0–40) 
for unvaccinated pregnant women. Overall, 22% 
of multiparous women had a prior history of a 
poor obstetric outcome (either preterm birth, 
stillbirth or neonatal death) with six (4%) of 
these having received IIV in pregnancy. Other 
differences in maternal demographics, comor-
bidities and risk factors between women who 
received IIV in pregnancy are shown in Table 2.
Birth outcomes
Low uptake of IIV during pregnancy limited 
the capacity for meaningful comparisons of 
birth outcomes between unvaccinated women 
(the referent group) and the small number of 
women who were vaccinated in pregnancy. The 
median gestational age at birth of the infant 
was 38 weeks (range 21–42 weeks) for both the 
unvaccinated and vaccinated pregnant women, 
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Figure 1: Study participants from 1+1 Healthy Start study, by IIV vaccination status, Northern 
Territory, Australia, 2003–2012.
 
 
 
 
 
 
 
 
Total ‘1+1HS’ cohort 
n= 594 women 
n= 721 pregnancies 
n= 731 infants  
Excluded: multiple births  
- 9 women 
- 9 pregnancies 
- 18 infants  
Excluded: unknown vaccination status 
- 3 women 
- 3 pregnancies 
- 3 infants  
Final ‘1+1HS IIV’ cohort 
n= 677 (97%) unvaccinated pregnancies 
n= 20 (3%) IIV vaccinated pregnancies 
N= 697 total pregnancies and infants 
Excluded: duplicate or missing data 
- 0 women 
- 6 pregnancies 
- 7 infants  
Excluded: vaccinated with dTpa (no IIV) 
- 6 women 
- 6 pregnancies 
- 6 infants 
Table 1: IIV uptake pre- and post-influenza A(H1N1)pdm09 in 1+1HS study participants, 
Northern Territory, Australia, 2003–2011.
Year of birth Number of births N vaccinated with IIV in pregnancy %
2003 1 0/1 (0%)
2004 122 0/122 (0%)
2005 142 0/142 (0%)
2006 139 0/139 (0%)
2007 Data not collected n/a
2008 Data not collected n/a
2009 44 6/44 (14%)
2010 153 1/153 (<1%)
2011 96 13/96 (14%)
Total 697 20/697 (3%)
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Table 2: Maternal characteristics, comorbidities and risk factors of 1+1HS study participants, and 
percentage who received IIV in pregnancy, Northern Territory, Australia, 2003–2012.
Characteristics Totaln (%)
Vaccinateda
influenza n (%)
Twin pregnancy 9/594 (2%) 0/9 (0%)
Parity (primiparous) 217/697 (31%) 5/217 (2%)
Antenatal care 1st trimester (Y/N) b 281/697 (42%) 11/281 (4%)
Smoking in pregnancy when recorded, (Yes) at 36wks 113/199 (57%) 6/113 (5%)
Previous poor obstetric outcomec 152/697 (22%) 6/152 (4%)
Rheumatic heart disease 41/697 (6%) 3/41 (7%)
Cardiac condition 62/697 (9%) 1/62 (2%)
Diabetesd 46/697 (7%) 2/46 (4%)
Renal disease 20/697 (3%) 0/20 (0%)
Asthma 9/697 (1%) 0/9 (0%)
Maternal anaemia 414/697 (59%) 13/414 (3%)
Pregnancy complicatione 374/697 (54%) 11/374 (3%)
Note: denominators differ due to missing data.
a number n (%) who received IIV in pregnancy that had comorbidity/risk factor
b Self-reported response at 1st antenatal visit
c Includes previous history of preterm birth, stillbirth, neonatal death (in multiparous women)
d Includes type 1, type 2 and gestational diabetes
e Includes threatened preterm labour, preterm rupture of membranes, antepartum haemorrhage, placental abruption, placenta praevia, 
UTI, STI, gestational hypertension, pre-eclampsia
with a small and neither clinically relevant or 
statistically significant difference in mean birth-
weights (3,001 g vs 3,175 g [95%CI -467 g, 119 
g, p=0.24]). Proportions of preterm births and 
LBW were similar between the unvaccinated and 
vaccinated group (Table 3), though there were 
proportionally more than three times as many 
infants born SGA in unvaccinated pregnancies, 
17% (111/660), compared to 5% (1/19) of IIV 
vaccinated pregnancies. Our time-dependent 
analysis found no evidence of an increased risk 
of preterm births, LBW or SGA infants when 
comparing women who received an IIV in preg-
nancy with unvaccinated pregnancies (Table 3). 
Adjusted HRs were not conducted due to insuf-
ficient numbers of vaccinated women for the 
model to support adjustment on multiple factors.
Discussion
Despite a nationally-funded seasonal IIV pro-
gram targeting Aboriginal pregnant women 
being recommended since 2000, only 3% of the 
Aboriginal women in our study received an 
IIV vaccination during their pregnancy dur-
ing 2003–2006 and 2009–2011. This very low 
coverage was particularly disconcerting given 
our study participants were women living in a 
remote setting with high rates of poverty and 
markedly high rates of smoking, comorbidities, 
birthing at a younger age, and pregnancy, birth 
and postnatal complications, similarly reported 
in remote-living Aboriginal women from the 
NT.25,26 Aboriginal women continue to incur 
significantly more adverse perinatal outcomes 
compared to other Australian women, particu-
larly stillbirths, preterm births, SGA and LBW 
infants.25,27 These infants experience higher 
rates of morbidity and mortality and are more 
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susceptible to vaccine-preventable infections 
compared to infants born at term.25,28 The long-
term sequelae for Aboriginal infants who are 
born preterm or LBW comprises substantially 
higher rates of chronic diseases and hospitalisa-
tions compared to non-Aboriginal adults.25,29
The first NT case of influenza A(H1N1)pdm09 
was detected on 29 May 2009.29 Coverage of IIV 
uptake in pregnancy was 0% in a pre influenza 
A(H1N1)pdm09 era (<2009). We expected uptake 
to be substantially higher than observed, and 
saw no evidence of improved or sustained vac-
cination coverage after a small increase during 
the pandemic (14%) and post pandemic (14%). It 
is not possible to determine whether this was a 
failure to report, under-ascertainment or refusal 
of vaccination, however similar studies have also 
reported low IIV uptake in pregnant Aboriginal 
women.30 Further, an existing vaccination 
record from the NTIR was detected for >98% of 
the participants in our study, and immunisation 
coverage is known to be high among Aboriginal 
infants from the NT.31 One study nested within a 
RCT examined pre- and post-influenza A(H1N1)
pdm09 IIV uptake in different Aboriginal com-
munities in the NT over a similar time period 
(2006–2011).30 This study found very low rates of 
seasonal IIV uptake (~4% verified) in pregnant 
Aboriginal women in a pre-influenza A(H1N1)
pdm09 period (n=3/71), with verified coverage 
increasing to ~42% (n=28/67) in the intra-
influenza A(H1N1)pdm09 period (2009–2010). 
Participant numbers for that study were small 
(N=138), with a relatively higher level of edu-
cation and less high-risk factors compared to 
remote-living Aboriginal women from the NT.26 
A NT bulletin showed IIV uptake in Aboriginal 
pregnant women during 2013 was ~30% 
(n=585/1,930) for those who birthed at RDH,32 
which is where our study population birthed. 
Whilst this shows a substantial increase in IIV 
uptake in pregnancy for Aboriginal women, the 
breakdown of remote- and very-remote-living 
status was not reported, therefore uptake of IIV 
in pregnancy is potentially not generalisable for 
the whole Aboriginal population who live in the 
Top End, and potentially an artefact of healthy, 
urban and outer-regional-living Aboriginal 
pregnant women accessing antenatal health 
care programs. A small survey in 2017 from 
Western Australia (WA) reported 37% (n=35/94) 
of Aboriginal women with a known vaccina-
tion status received an IIV in pregnancy.33 The 
women in the WA study were largely metropoli-
tan/urban living, and it is unclear what propor-
tion, if any, were remote-and very remote-living. 
Maternal demographic characteristics, comor-
bidities, risk factors and adverse birth outcomes 
were not reported in the WA survey.
Australian literature has demonstrated that 
advice on maternal vaccination from a pregnant 
woman’s healthcare provider is the key influ-
encer of vaccination uptake in pregnancy,17 and 
that if given the opportunity, Aboriginal women 
are accepting of IIV in pregnancy,33 particularly 
if community consultation and engagement 
with local communities is a priority.34 Providing 
evidence of IIV uptake, safety and effectiveness 
in pregnancy in a consistent, appropriate and 
culturally acceptable way for Aboriginal women 
and their families is also essential.35 Providing 
local support of maternal vaccination programs 
to antenatal healthcare workers may be critical in 
order to give remote-living pregnant Aboriginal 
women an informed, positive recommendation 
regarding maternal vaccination.
The 2017 Aboriginal and Torres Strait Islander 
Health Performance Framework report of the 
NT36 highlighted an important aim was to map 
the health needs of remote Aboriginal women 
and infants to the health services available, in 
order to address low birthweight, smoking dur-
ing pregnancy and low antenatal care attend-
ance. Addressing the high burden of respiratory 
illness in pregnancy, in women of childbearing 
age, and in young infants is also warranted 
in this population. Acknowledging the poor 
uptake of IIV we observed in our study, increas-
ing IIV coverage in pregnancy would be a step 
forward, provided safety and effectiveness can 
be demonstrated.
The international literature on the safety of IIV 
in pregnancy are encouraging,37,38 but there are 
persistent gaps in the evidence for high-risk 
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populations, such as remote-living Indigenous 
peoples, that need to be addressed. Data are 
lacking on the safety of vaccination in the first 
trimester of pregnancy, and on safety endpoints 
such as miscarriage, preterm births, stillbirths, 
LBW and SGA infants. One Australian study 
published in 2018 found no increased risk in 
preterm births, low birthweight or SGA infants 
in pregnant women who received a seasonal IIV 
compared to unvaccinated pregnant women,39 
however only 3% of this national cohort (N=8,827 
mother-infant pairs) were Aboriginal women. 
Prior to 2015, analyses were largely limited to 
specific vaccines used during the influenza 
A(H1N1) pandemic,40 and observational studies 
used in a meta-analysis38 were non-Indigenous 
women living in well-resourced populations of 
North America and Europe.
Strengths and limitations
A strength of this study lies in the rich, rigorous 
data collection methodologies and the ability 
to ascertain maternal vaccination status for all 
study participants. Our sample size of 697 preg-
nancies among 582 remote-living Aboriginal 
women is larger than other available studies, and 
through data linkage rather than self-report, we 
were able to establish seasonal IIV uptake based 
on confirmed dates of vaccination. Data linkage 
also enabled us to improve the internal validity 
of the study sample. We were able to retrieve 
missing maternal and infant data, enabling us to 
identify duplicate entries and to correct illogical 
dates of maternal and infant births. Our small 
numbers of vaccinated pregnancies were unex-
pected and as such, are a limitation, as was the 
inability to report on women who suffered mis-
carriages <20 weeks gestation. We did however, 
reduce the risk of introducing immortal time 
bias by applying the recommended methodol-
ogy for conducting time-dependent analyses.
There are currently no programs to system-
atically monitor the uptake, safety and effec-
tiveness of IIV in pregnancy, so it is difficult to 
determine where the procedural gaps exist for 
remote-living Aboriginal pregnant women of 
the NT. Until such programs are in place, well-
conducted observational studies and data link-
age studies remain important, particularly for 
planning and in preparation for future influenza 
pandemics.
Conclusion
In Australia, an operational period of a nation-
ally recommended seasonal IIV has been in 
place for almost 20 years. Despite the funded 
IIV program targeting pregnant Aboriginal 
women, vaccine uptake remained <4% in our 
participants from remote and very remote 
communities in the NT across 2003–2006 and 
2009–2011. Reasons for this policy failure dur-
ing this time period are unknown, with further 
research needed. Providing evidence of the 
safety and effectiveness of IIV in pregnancy 
may contribute to the willingness of women and 
health care providers to implement this policy.
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